Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.50 +1.96%

+$0.19 today

Market cap
$66.22M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.07M

Average 1.40M

Returns on capital

Atara Biotherapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-84.9%

avg -184.8%

ROIC

222.7%

avg -32.4%

ROA

161.5%

avg -178.8%

Analysis

ROIC is currently the strongest return metric at 222.7% versus its period average of -32.4%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Anhco Nguyen

President, Chief Executive Officer & DirectorUSD 1.07M53132.78K1.47%

Alex Chapman

Vice President of Corporate Communications & Investor Relations————

Jim Sesic

Senior Vice President of Regulatory Affairs————

Kevin G. Sarney

Interim Chief Financial Officer—610<0.01%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 17, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

2

$5.74M

Sells

13

$3.79M

Net Transaction Value

+$1.95M

Net buying

Most Active

Nguyen AnhCo

6 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Sep 4, 26

Cherry Brian N

Direct

Buy$1M
Aug 17, 26

Nguyen AnhCo

Direct

Sell$40.9K
May 18, 26

Nguyen AnhCo

Direct

Sell$47.8K
May 18, 26

Grant-Huerta Yanina

Direct

Sell$22K
May 7, 26

Panacea Innovation Ltd

Indirect

Sell$3.2M
May 7, 26

EcoR1 Capital, LLC

Indirect

Buy$4.7M
Mar 2, 26

Grant-Huerta Yanina

Direct

Sell$121.8
Mar 2, 26

Grant-Huerta Yanina

Direct

Sell$8.1K
Mar 2, 26

Grant-Huerta Yanina

Direct

Sell$1.9K
Mar 2, 26

Grant-Huerta Yanina

Direct

Sell$508.3

1–10 of 15

Summary

Insiders reported 2 buys worth $5.74M and 13 sells worth $3.79M over the last 12 months. That adds up to net buying of $1.95M. Nguyen AnhCo was the most active insider with 6 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
+1.5% (5yr)1 analysts
RevenueN/AN/A+23.9%
-5.3% (5yr)2 analysts
Net IncomeN/AN/AN/A
+1.5% (5yr)2 analysts
EBITN/AN/AN/A
+6.5% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +23.9% over three years. Forward estimates point to EBIT at +6.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Atara Biotherapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about ATRA's management, answered from reported figures.

Who manages ATRA?

Atara Biotherapeutics, Inc. (ATRA) lists 4 active executives. The top listed executive is Alex Chapman, Vice President of Corporate Communications & Investor Relations.

Are ATRA insiders buying or selling?

Recent insider activity shows net selling of $10.67M.